Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Amyris, Biogen pair up for cell line alternatives
September 2016
SHARING OPTIONS:

EMERYVILLE, Calif.—Industrial bioscience company Amyris Inc. has begun a funded partnership with Biogen Inc. to explore the use of Amyris’ advanced microbe engineering technology for evaluating and developing host microorganisms as alternatives to mammalian cell lines for producing therapeutic recombinant proteins. No financial details were disclosed.
 
“Over the course of the partnership, Amyris will utilize its leading strain engineering and screening technology to evaluate the tractability of each selected species as a new potential cell line for recombinant protein production,” said Joel Cherry, president of research and development at Amyris. “Selected candidates from the initial work will go into a second phase of development to create commercially robust cell lines for use in drug manufacturing.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.